Dose Escalation of Ara-C May Improve Response Rates in a Subgroup of Chronic Myeloid Leukemia Patients with Poor Response to Interferon-α and Low-dose Ara-C

References

• Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J. L., Maloisel F., et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myeloid leukemia. N. Engl. J. Med. 1997; 337: 223–229
   PubMed Web of Science ®Google Scholar
• Rosti G., Bonifazi F., Trabacchi E., De Vivo A., Martinelli G., Bassi S., et al. Results of a national prospective randomized trial comparing interferon and interferon + low dose cytarabine in early chronic phase chronic myelogenous leukemia: rates of hematologic and cytogenetic responses and effects of survival. Haematologica 2000; 85: 24
   Google Scholar
• Kantarjian H. M., O'Brien S., Smith T. L., Rios M. B., Cortes J., Beran M., et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J. Clin. Oncol. 1999; 17: 284–292
   PubMed Web of Science ®Google Scholar
• Thaler J., Hilbe W., Apfelbeck U., Linkesch W., Sill H., Seewann H., et al. Interferon-alpha-2c and LD-ara-C for the treatment of patients with CML: preliminary results of the Austrian multicenter phase II study. Leuk. Res. 1997; 21: 75–80
   PubMed Web of Science ®Google Scholar
• Arthur C. K., Ma D. D.F. Combined interferon alpa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol. 1993; 89((Suppl. 1))15–21
   PubMedGoogle Scholar
• Lindauer M., Domkin D., Döhner H., Kolb H. J., Neubauer A., Huhn D., et al. Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia. Br. J. Haematol. 1999; 106: 1013–1019
   PubMed Web of Science ®Google Scholar
• Miller A. B., Hoogstraten B., Straquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Cox E. B., Baccarani M., Tura S., Gomez G. A., Robertson J. E., et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., McCredie K. B., Trujillo J., Keating M. J., Gutterman J. U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N. Engl. J. Med. 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Guilhot F., Dreyfus B., Brizard A., Huret J. L., Tanzer J. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside. Leuk. Lymph. 1991; 4: 49–55
   PubMed Web of Science ®Google Scholar
• Silver R. T., Benn P., Szatrowski T. P., Verma R., Gutfriend A. Infusional cytosine arabinoside (ara-C) and recombinant interferon-alpha (rIFN-alpha) for the treatment of chronic myeloid leukemia (CML). Proc. Asco 1990; 9: 209
   Google Scholar
• Kantarjian H. M., Keating M. J., Estey E. H., O'Brian S., Pierce S., Beran M., et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J. Clin. Oncol. 1992; 10: 772–778
   PubMed Web of Science ®Google Scholar
• Thaler J., Fluckinger T., Huber H., Lang A., Abbrederis C., Seewann H., et al. 'Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2c and low-dose cytosine arabinoside. Leuk. Res. 1993; 17: 711–715
   PubMed Web of Science ®Google Scholar
• Braess J., Freund M., Hanauska A., Heil G., Kaufmann C., Kern W., et al. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma—phase I/II studies and pharmacokinetics. Leukemia 1998; 12: 1618–1626
   PubMed Web of Science ®Google Scholar
• Guilhot F., Harousseau J. L., Fiere D., Rapp M. J., Michallet M., David M., et al. Phase III trial of ara-C prodrug YNK01 in chronic myelogenous leukemia patients: hematologic and cytogenetic responses. Proc. Asco 1996; 15: 449
   Google Scholar
• Guilhot F., Maloisel F., Guyotat D., Ifrah N., Michallet M., Reiffers J., et al. A phase II study to assess efficacy and safety of interferon α 2b (IFN) in combination with oral cytarabine ocfosfate (YNK01) in patients with chronic myelogenous leukemia (CML). Blood 1998; 92((Suppl. 1))627a
   Google Scholar
• Kühr T., Eisterer W., Apfelbeck U., Linkesch W., Bechter O., Zabernigg A., et al. Treatment of patients with advanced chronic myelogenous leukemia with interferonalpha-2b and continuous oral cytarabine ocfosfate (YNKO1): a pilot study. Leuk. Res. 2000; 24: 583–587
   PubMed Web of Science ®Google Scholar